Table 1.
Baseline and change in study end points from baseline expressed as medians (25th, 75th percentile)
| Placebo (n = 8) |
Testosterone gel (n = 7) |
T gel + Dutasteride (n = 7) |
T gel + DMPA (n = 7) |
|||||
|---|---|---|---|---|---|---|---|---|
| Wk 0 Baseline | Wk 10 End of treatment | Wk 0 Baseline | Wk 10 End of treatment | Wk 0 Baseline | Wk 10 End of treatment | Wk 0 Baseline | Wk 10 End of treatment | |
| LH (IU/liter) | 4.0 (3.5, 5.6) | 5.1 (2.7, 5.9) | 3.9 (2.7, 5.5) | 1.3 (0.4, 1.8)a | 5.3 (4.2, 6, 6) | 3.6 (2.7, 6.7) | 3.2 (2.7, 4.0) | 0.5 (0.0, 2.6)a |
| FSH (IU/liter) | 3.6 (2.6, 4.4) | 3.5 (2.7, 4.7) | 3.3 (2.6, 3.7) | 1.3 (0.5, 1.8)a | 4.0 (2.4, 5.5) | 2.9 (1.1, 3.6)a | 2.8 (2.6, 4.2) | 1.3 (0.1, 2.1)a |
| SHBG (nmol/liter) | 33 (24, 45) | 34 (25, 48) | 36 (13, 50) | 34 (16, 55) | 38 (26, 52) | 43 (26, 58) | 33 (17, 38) | 31 (13, 52) |
| DHEA (ng/ml) | 3.8 (3.0, 4.7) | 4.3 (2.7, 5.5) | 6 (2.9, 9.4) | 3.5 (2.0, 7.5)a | 4.2 (2.5, 6.0) | 3.8 (3.5, 6.3) | 4.2 (2.4, 5.2) | 3.2 (2.1, 4.0) |
| AED (ng/ml) | 0.9 (0.7, 1.2) | 0.9 (0.8, 1.1) | 1.1 (0.9, 1.2) | 0.9 (0.8, 1.3) | 0.9 (0.7, 0.9) | 1.8 (1.3, 3.7)a,b | 1.0 (0.6, 1.3) | 0.7 (0.6, 1.0) |
| DHT (ng/ml) | 0.5 (0.4, 0.5) | 0.5 (0.4, 0.6) | 0.6 (0.4, 0.9) | 1.8 (1.2, 2.5)a,b | 0.7 (0.6, 1.0) | 0.5 (0.3, 0.5)a | 0.6 (0.4, 0.8) | 0.6 (0.2, 1.8) |
| T (ng/ml) | 3.9 (3.8, 5.0) | 4.0 (2.9, 5.6) | 3.9 (2.9, 5.9) | 4.4 (3.2, 6.2) | 4.8 (3.8, 6.3) | 7.0 (4.4, 12.4)a,b | 4.0 (3.0, 5.8) | 1.8 (1.3, 2.9)a,b |
| Free T (pg/ml) | 63 (59, 77) | 57 (45, 83) | 73 (58, 89) | 65 (56, 106) | 73 (64, 92) | 104 (79, 122)a,b | 73 (62, 103) | 58 (37, 80) |
| E2 (pg/ml) | 63 (59, 77) | 57 (45, 83) | 73 (58, 89) | 65 (56, 106) | 73 (64, 92) | 104 (79, 122)a,b | 73 (62, 103) | 58 (37, 80) |
| PSA (ng/ml) | 0.7 (0.6, 1.0) | 0.8 (0.7, 1.2) | 0.7 (0.4, 1.1) | 0.9 (0.3, 1.2) | 0.9 (0.7, 1.1) | 0.7 (0.7, 1.1) | 0.5 (0.4, 0.6)c | 0.4 (0.4, 0.6) |
| Prostate volume (ml) | 25 (16, 29) | 22 (18, 24)a | 15 (14, 19) | 16 (14, 17) | 15 (13, 21) | 15 (13, 19) | 19 (14, 21) | 17 (14, 19) |
E2, Estradiol.
a
P < 0.05 vs. baseline.
b
P < 0.05 compared with placebo and other groups at wk 10.
c
P < 0.05 compared with placebo at baseline.